Liver transplant outcomes in a newly started program

Tokan Sultanaliev, Assan Zhexembayev, Adilbek Mukazhanov, Bakhyt Zharkymbekov, Gani Kuttymuratov, Zhanat Spatayev, Bauyrzhan Ibrayev, Kakharman Yesmembetov, Aiymkul Ashimkhanova, M. Els Asykbayev

Research output: Contribution to journalArticle

Abstract

Objectives: Kazakhstan is experiencing a high demand for liver transplants. More than 1000 patients have end-stage liver disease in the country, and liver transplant is the only viable option for their treatment. Materials and Methods: Liver transplant patients, treated from February 2013 to December 2014, were included in this retrospective analysis. Results: From February 2013 to December 2014, seven patients received a liver transplant in our center (1 pediatric patient was excluded). Deceased liver recipients’ (n = 3) median age was 52 years and median Model for End-Stage Liver Disease score 9. The indication for transplant was uncontrolled portal hypertension due to autoimmune liver disease. Cadaveric donors’ median age was 45 years. Recipients’ intensive care unit stay was > 5 days, time on inotropic support was > 3 days. Mean cold ischemic time was > 6 hours, and secondary ischemic time was 67 minutes. One patient in the deceased donor transplant group died during postoperative week 1 from hepatic artery thrombosis. Living donor liver recipients’ (n = 3) median age was 47 years (43-48 y) and median Model for End-Stage Liver Disease score was 17 (range 14-20). Liver disease was hepatitis virus related (hepatitis C virus in 1 patient and hepatitis B and D virus in 2 patients). Mean cold ischemic time was 0.43 hours, and mean secondary ischemic time was 64 minutes. One recipient in the living donor liver group died early in the postoperative period from hemorrhage. Conclusions: Our experience was insufficient to adequately assess morbidity and survival rates in patients for whom the longest follow-up was 25 months. However, no episodes of rejection were observed. Survival rates between living and deceased donor recipients were equivalent, although cadaveric-donor liver conditions were imperfect. This analysis demonstrates the necessity for timely diagnosis of surgical complications, which accounted for all mortality incidence in our series.

Original languageEnglish
Pages (from-to)120-122
Number of pages3
JournalExperimental and Clinical Transplantation
Volume13
DOIs
Publication statusPublished - Nov 1 2015
Externally publishedYes

Fingerprint

Transplants
Liver
End Stage Liver Disease
Living Donors
Cold Ischemia
Tissue Donors
Liver Diseases
Survival Rate
Kazakhstan
Hepatitis Delta Virus
Postoperative Hemorrhage
Hepatitis Viruses
Hepatic Artery
Portal Hypertension
Postoperative Period
Hepatitis B virus
Hepacivirus
Autoimmune Diseases
Intensive Care Units
Thrombosis

Keywords

  • Deceased donor liver transplantion
  • Endstage liver disease
  • Hepatitis
  • Liver cirrhosis
  • Living donor liver transplantion

ASJC Scopus subject areas

  • Transplantation

Cite this

Sultanaliev, T., Zhexembayev, A., Mukazhanov, A., Zharkymbekov, B., Kuttymuratov, G., Spatayev, Z., ... Asykbayev, M. E. (2015). Liver transplant outcomes in a newly started program. Experimental and Clinical Transplantation, 13, 120-122. https://doi.org/10.6002/ect.tdtd2015.P66

Liver transplant outcomes in a newly started program. / Sultanaliev, Tokan; Zhexembayev, Assan; Mukazhanov, Adilbek; Zharkymbekov, Bakhyt; Kuttymuratov, Gani; Spatayev, Zhanat; Ibrayev, Bauyrzhan; Yesmembetov, Kakharman; Ashimkhanova, Aiymkul; Asykbayev, M. Els.

In: Experimental and Clinical Transplantation, Vol. 13, 01.11.2015, p. 120-122.

Research output: Contribution to journalArticle

Sultanaliev, T, Zhexembayev, A, Mukazhanov, A, Zharkymbekov, B, Kuttymuratov, G, Spatayev, Z, Ibrayev, B, Yesmembetov, K, Ashimkhanova, A & Asykbayev, ME 2015, 'Liver transplant outcomes in a newly started program', Experimental and Clinical Transplantation, vol. 13, pp. 120-122. https://doi.org/10.6002/ect.tdtd2015.P66
Sultanaliev T, Zhexembayev A, Mukazhanov A, Zharkymbekov B, Kuttymuratov G, Spatayev Z et al. Liver transplant outcomes in a newly started program. Experimental and Clinical Transplantation. 2015 Nov 1;13:120-122. https://doi.org/10.6002/ect.tdtd2015.P66
Sultanaliev, Tokan ; Zhexembayev, Assan ; Mukazhanov, Adilbek ; Zharkymbekov, Bakhyt ; Kuttymuratov, Gani ; Spatayev, Zhanat ; Ibrayev, Bauyrzhan ; Yesmembetov, Kakharman ; Ashimkhanova, Aiymkul ; Asykbayev, M. Els. / Liver transplant outcomes in a newly started program. In: Experimental and Clinical Transplantation. 2015 ; Vol. 13. pp. 120-122.
@article{8b6f7361b58548c895d56559698983f2,
title = "Liver transplant outcomes in a newly started program",
abstract = "Objectives: Kazakhstan is experiencing a high demand for liver transplants. More than 1000 patients have end-stage liver disease in the country, and liver transplant is the only viable option for their treatment. Materials and Methods: Liver transplant patients, treated from February 2013 to December 2014, were included in this retrospective analysis. Results: From February 2013 to December 2014, seven patients received a liver transplant in our center (1 pediatric patient was excluded). Deceased liver recipients’ (n = 3) median age was 52 years and median Model for End-Stage Liver Disease score 9. The indication for transplant was uncontrolled portal hypertension due to autoimmune liver disease. Cadaveric donors’ median age was 45 years. Recipients’ intensive care unit stay was > 5 days, time on inotropic support was > 3 days. Mean cold ischemic time was > 6 hours, and secondary ischemic time was 67 minutes. One patient in the deceased donor transplant group died during postoperative week 1 from hepatic artery thrombosis. Living donor liver recipients’ (n = 3) median age was 47 years (43-48 y) and median Model for End-Stage Liver Disease score was 17 (range 14-20). Liver disease was hepatitis virus related (hepatitis C virus in 1 patient and hepatitis B and D virus in 2 patients). Mean cold ischemic time was 0.43 hours, and mean secondary ischemic time was 64 minutes. One recipient in the living donor liver group died early in the postoperative period from hemorrhage. Conclusions: Our experience was insufficient to adequately assess morbidity and survival rates in patients for whom the longest follow-up was 25 months. However, no episodes of rejection were observed. Survival rates between living and deceased donor recipients were equivalent, although cadaveric-donor liver conditions were imperfect. This analysis demonstrates the necessity for timely diagnosis of surgical complications, which accounted for all mortality incidence in our series.",
keywords = "Deceased donor liver transplantion, Endstage liver disease, Hepatitis, Liver cirrhosis, Living donor liver transplantion",
author = "Tokan Sultanaliev and Assan Zhexembayev and Adilbek Mukazhanov and Bakhyt Zharkymbekov and Gani Kuttymuratov and Zhanat Spatayev and Bauyrzhan Ibrayev and Kakharman Yesmembetov and Aiymkul Ashimkhanova and Asykbayev, {M. Els}",
year = "2015",
month = "11",
day = "1",
doi = "10.6002/ect.tdtd2015.P66",
language = "English",
volume = "13",
pages = "120--122",
journal = "Experimental and Clinical Transplantation",
issn = "1304-0855",
publisher = "Baskent University",

}

TY - JOUR

T1 - Liver transplant outcomes in a newly started program

AU - Sultanaliev, Tokan

AU - Zhexembayev, Assan

AU - Mukazhanov, Adilbek

AU - Zharkymbekov, Bakhyt

AU - Kuttymuratov, Gani

AU - Spatayev, Zhanat

AU - Ibrayev, Bauyrzhan

AU - Yesmembetov, Kakharman

AU - Ashimkhanova, Aiymkul

AU - Asykbayev, M. Els

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objectives: Kazakhstan is experiencing a high demand for liver transplants. More than 1000 patients have end-stage liver disease in the country, and liver transplant is the only viable option for their treatment. Materials and Methods: Liver transplant patients, treated from February 2013 to December 2014, were included in this retrospective analysis. Results: From February 2013 to December 2014, seven patients received a liver transplant in our center (1 pediatric patient was excluded). Deceased liver recipients’ (n = 3) median age was 52 years and median Model for End-Stage Liver Disease score 9. The indication for transplant was uncontrolled portal hypertension due to autoimmune liver disease. Cadaveric donors’ median age was 45 years. Recipients’ intensive care unit stay was > 5 days, time on inotropic support was > 3 days. Mean cold ischemic time was > 6 hours, and secondary ischemic time was 67 minutes. One patient in the deceased donor transplant group died during postoperative week 1 from hepatic artery thrombosis. Living donor liver recipients’ (n = 3) median age was 47 years (43-48 y) and median Model for End-Stage Liver Disease score was 17 (range 14-20). Liver disease was hepatitis virus related (hepatitis C virus in 1 patient and hepatitis B and D virus in 2 patients). Mean cold ischemic time was 0.43 hours, and mean secondary ischemic time was 64 minutes. One recipient in the living donor liver group died early in the postoperative period from hemorrhage. Conclusions: Our experience was insufficient to adequately assess morbidity and survival rates in patients for whom the longest follow-up was 25 months. However, no episodes of rejection were observed. Survival rates between living and deceased donor recipients were equivalent, although cadaveric-donor liver conditions were imperfect. This analysis demonstrates the necessity for timely diagnosis of surgical complications, which accounted for all mortality incidence in our series.

AB - Objectives: Kazakhstan is experiencing a high demand for liver transplants. More than 1000 patients have end-stage liver disease in the country, and liver transplant is the only viable option for their treatment. Materials and Methods: Liver transplant patients, treated from February 2013 to December 2014, were included in this retrospective analysis. Results: From February 2013 to December 2014, seven patients received a liver transplant in our center (1 pediatric patient was excluded). Deceased liver recipients’ (n = 3) median age was 52 years and median Model for End-Stage Liver Disease score 9. The indication for transplant was uncontrolled portal hypertension due to autoimmune liver disease. Cadaveric donors’ median age was 45 years. Recipients’ intensive care unit stay was > 5 days, time on inotropic support was > 3 days. Mean cold ischemic time was > 6 hours, and secondary ischemic time was 67 minutes. One patient in the deceased donor transplant group died during postoperative week 1 from hepatic artery thrombosis. Living donor liver recipients’ (n = 3) median age was 47 years (43-48 y) and median Model for End-Stage Liver Disease score was 17 (range 14-20). Liver disease was hepatitis virus related (hepatitis C virus in 1 patient and hepatitis B and D virus in 2 patients). Mean cold ischemic time was 0.43 hours, and mean secondary ischemic time was 64 minutes. One recipient in the living donor liver group died early in the postoperative period from hemorrhage. Conclusions: Our experience was insufficient to adequately assess morbidity and survival rates in patients for whom the longest follow-up was 25 months. However, no episodes of rejection were observed. Survival rates between living and deceased donor recipients were equivalent, although cadaveric-donor liver conditions were imperfect. This analysis demonstrates the necessity for timely diagnosis of surgical complications, which accounted for all mortality incidence in our series.

KW - Deceased donor liver transplantion

KW - Endstage liver disease

KW - Hepatitis

KW - Liver cirrhosis

KW - Living donor liver transplantion

UR - http://www.scopus.com/inward/record.url?scp=84953851123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953851123&partnerID=8YFLogxK

U2 - 10.6002/ect.tdtd2015.P66

DO - 10.6002/ect.tdtd2015.P66

M3 - Article

VL - 13

SP - 120

EP - 122

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1304-0855

ER -